Ayrolles A, Ellul P, Trebossen V, Houhou‐Fidouh N, Bonacorsi S, Descamps D, Delorme R. Is SARS‐CoV‐2 seroconversion a risk factor for severe and acute psychiatric symptoms in children?
Neuropsychopharmacol Rep 2022;
42:218-220. [PMID:
35257512 PMCID:
PMC9216372 DOI:
10.1002/npr2.12236]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 01/19/2022] [Accepted: 01/20/2022] [Indexed: 12/02/2022] Open
Abstract
Aims
Since the beginning of the COVID pandemic, studies reported an increase in children’s mental health issues and questioned the impact of SARS‐CoV‐2 on psychiatric symptoms.
Methods
We compared COVID seroconversion in children hospitalized with acute, severe psychiatric symptoms (n = 52) with the sex‐ and age‐matched control group (n = 52) living in the same low‐income geographic area and sampled during the same time period.
Results
Contrary to our hypothesis, we observed less seroconverted children with psychiatric conditions 9.61% (95% CI, 3.59‐21.80) vs 34.61% (95% CI, 22.33‐49.16; χ2 = 14.7, P = 1.24E−4; OR = 0.20; 95% CI, 0.05‐0.64).
Conclusion
This suggests a lower direct impact of SARS‐CoV‐2 compared with the impact of mitigation strategies on psychiatric symptom deterioration in children reported since early stages of the pandemic.
Collapse